From June 2023, all our podcasts will move to https://lupusbmj.podbean.com.
You can continue with your subscription on your favourite podcast App.

Lupus Science and Medicine is a global, peer reviewed, Open Access, online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. It is the first lupus-specific Open Access journal in the world and was developed in response to the need for a barrier-free forum for publication of groundbreaking studies in lupus.
* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

Lupus Science and Medicine podcast

Duane Peters from the Lupus Foundation of America interviews the Lupus Science & Medicine Editors-in-Chief, Professor Jill Buyon and Professor Ronald van Vollenhoven. They discuss the recent release of LSM's first Journal Impact Factor™, explaining how it has been calculated, and what it means for the journal, its authors and readers.  

Access all the LSM journal metrics: https://lupus.bmj.com/pages/top-cited-articles/ and https://lupus.bmj.com/pages/about/.

Lupus Science & Medicine

LSM's first Journal Impact Factor™

Duane Peters from the Lupus Foundation of America talks to Dr Cristina Drenkard from Emory University and Dr Teresa Brady from Clarity Consulting and Communications, both based in Atlanta, USA. 

They discuss their paper on the relationship between levels of self-efficacy and health behaviours and outcomes in black women with SLE. Their study specifically evaluated the associations between age, educational level and depression in SLE patients and the degree of pain and fatigue they experienced. These findings may help predict who might benefit most from self-efficacy-enhancing interventions to improve quality of life.

Access the article: https://lupus.bmj.com/content/9/1/e000566

Lupus Science and Medicine Podcast Series

What's the relationship between self-efficacy and quality of life in SLE patients?

Duane Peters from the Lupus Foundation of America interviews Professor Ronald van Vollenhoven from the Amsterdam University Medical Centers in the Netherlands and Dr Cynthia Aranow from the Feinstein Institute for Medical Research in New York, USA. 

They discuss the efforts of the DORIS international task force to agree on a single definition of remission in systemic lupus erythematosus, which they hope will ensure that clinicians, patients and researchers in the field are all working towards the same outcome. 

Access the article: https://lupus.bmj.com/content/8/1/e000538

Lupus Science and Medicine podcast series

Defining remission in systemic lupus erythematosus

Duane Peters from the Lupus Foundation of America interviews Dr Peter Izmirly from New York University and Dr Elizabeth Ferucci from the Alaska Native Tribal Health Consortium, both in the USA. 

They discuss the establishment of a network of population-based lupus patient registries in the USA and how these have been used to estimate the incidence rate of systemic lupus erythematosus using standardised data stratified by sex, race and ethnicity.

Access the article: https://lupus.bmj.com/content/8/1/e000614

Using patient registries to estimate SLE incidence rate in the USA

Duane Peters from the Lupus Foundation of America interviews Dr Gary Gilkeson from the Medical University of South Carolina about a phase I trial into the use of mesenchymal stromal cells (MSC) in refractory lupus patients in the USA, following impressive results of clinical improvement resulting from this therapy in China. 
The trial indicated that infusions of MSCs derived from the umbilical cord are safe and may be effective in treating mild to moderate systemic lupus erythematosus, with minimal adverse effects. 
Access the article: http://dx.doi.org/10.1136/lupus-2022-000704

Mesenchymal stromal cells: a potential new SLE treatment option?

Testet euer Wissen mit interaktiven Übungen: 

https://bit.ly/Top-Thema_Ewige-Chemikalien-Gefahr-fuer-Natur-und-Mensch

Mit dem Top-Thema könnt ihr euch gleichzeitig über Neues aus aller Welt informieren und euren Wortschatz erweitern. Wir bieten euch zwei leicht verständliche Berichte mit Vokabelangaben und Fragen zum Text pro Woche. 

Hier geht's zur Übersichtsseite: dw.com/topthema

Deutsch lernen (B1) | „Ewige Chemikalien“ – Gefahr für Natur und Mensch

Klickt hier, um zum Manuskript zu gelangen:

http://bit.ly/Deutschlernen_Langsam-Gesprochene-Nachrichten_17032023

Die Langsam gesprochenen Nachrichten der Deutschen Welle bieten von Montag bis Samstag aktuelle Tagesnachrichten aus aller Welt. Das langsam und verständlich gesprochene Audio trainiert das Hörverstehen. Zusätzlich gibt es den vollständigen Text zum Mitlesen. Die Audio-Datei kann auch heruntergeladen werden.

Hier geht's zur Übersichtsseite: dw.com/langsamenachrichten

Deutsch lernen (B2/C1) | Langsam Gesprochene Nachrichten vom 17.03.2023

Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation between the decrease in urinary CD163 levels and the response to Belimumab treatment in Lupus Nephritis trials. The conversation provides important insights into the efficacy of this treatment option and potential biomarker use for personalized and precision medicine in the future.
Read the article: http://dx.doi.org/10.1136/lupus-2022-000763

Biomarker reduction indicates treatment response to Belimumab

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Carien Creutzberg, Nanda Horeweg, and Alexandra Leary to discuss the RAINBO trials. Carien Creutzberg is Professor of Radiation Oncology at Leiden University Medical Center, the Netherlands. She specializes in research and treatment of gynecological cancers and has been the initiator and principal investigator of the four PORTEC trials and the TransPORTEC consortium. She is current chair of the GCIG Endometrial Cancer Committee and past Council member of ESGO and IGCS. Nanda Horeweg is senior researcher at the department of Radiation Oncology of Leiden University Medical Center, the Netherlands. She is one of the principal investigators of the PORTEC team and the international coordinator of the RAINBO program of clinical trials. Alexandra Leary, MD, PhD, is a medical oncologist specializing in gynecological cancers at Gustave Roussy Cancer Center in France. She is the CI for the RAINBO-RED trial and member of the TransPORTEC Consortium. She is current chair of the GCIG Phase II committee, gyne track chair for ESMO Asia, and past gyne track chair for ESMO.

RAINBO Trials with Carien Creutzberg, Nanda Horeweg, and Alexandra Leary

Mohamed Hedi Agrebi  Irdha 3lina - محمد الهادي العقربي إرضي علينا يا لُمّيمَة

Love Is My Religion

Araf

- و شيء- 
  اداء صوت :يسر مشفر
نص:  خديجه بكوش

و شيء- نص:  خديجه بكوش / اداء صوت :يسر مشفر

وقتاش القمرة تتزرع نوارة
ونقطف من خدودك ضحكة
تيبسلي دمعتي الغداره
ووقتاش يرجعلي ولفي
وتتحل ثنايا الرزق
والحوت يرجع يسرح
قدام ديار البحاره
ووقتاش يبرد جاشي
و تخطاني التنهيده
و نكرهو ضو لمدينه
ونحسبو نجوم الدشره
و كي نبردو مع رياح لفجاري
نفرشلك من كل زهره
غطاء في بالي
وكي تنعس يدي المكبشه
في يدك
و تغير من أختها السارحه
في بدنك
تسألها شوصلها لغادي واش بلها
بعرقنا

دين عشقتك
و يهلك شهاوينا
و يهلك طريق السواني
علاش فاضح خطاوينا
------------------------------------------- #سيف
تي علاش نغزرو مالشباك
وشمشنا عشقة متصدرة في ايدينا
تي وقتاش الليل يطل ؟
ويديك كي باب قلبي تتحل
انت السارية وانا لبحر
ووقتاش نعطيك بوسة مرصوصة
ونلبسك فرد مرة كي الخوصة
ويكمل هبالنا في وسط الحوسة

ووقتاش نحمّلك بالراحة
كي قطرة نو ستناوها الفلاّحة
كي غمضة نوم عاملة مرتاحة

ووقتاش نشدّك من يديك
وفي تراكن جاشي ندور بيك
ونورّيك ... ونعبث بيك
تي شبيك ؟
ماتفهمش ... ما تعرفش :

قداش سألت روحي
في الساعة مرّات
وقداش كتبتلك
حروف ماتقرات

تي وقتاش
يصفى لهوا
من دخان لمعامل
ووقتاش يرجع الصفا
وترجع لنفس لعمايل
ووقتاش
تتعدى بجنبي وماتحسبهاش
ترجع تتكى عندي وما تتغطاش
تزيدني دقة في روحي وماتحقرهاش

ونرجعو نحسبو للعشرة
ونتفكرو إلي بيناتنا عشرة
ونزيدو شوية للبرشة

تي يزي مالبعد وكل منامة حرشة
ويزي ما عملت فيها بهلولة وطرشة

الشي هذا لاهو متاعنا ولا يخرج علينا
لا ينفعنا ولا يفهم حر شهاوينا
والطريق الي ماشية فيه عمرو ما يواتينا

لازم ترجع ليالينا
ويرجع كيفك عامل مغناني
وبنة البعد تزيد تشهينا ...
وترجع تقرب خطاوينا
------------------------------------------------- #أمين
: نص مشترك 
[Amine.G] & سيف الزين

LSM's first Journal Impact Factor™

BMJ talk medicine

Related tracks